IndustryCompany release

Geron's Rytelo sales reach $60.1m in Q3 as European launch begins

🇺🇸 Geron Corp (GERN) · Wed 04 Nov 2026

Geron reported a 5% quarterly rise in Rytelo sales and a small profit, lowered its 2026 operating expense guidance and discontinued its Phase 3 IMpactMF myelofibrosis trial.

Geron reported net sales of $60.1 million for Rytelo (imetelstat) in the third quarter of 2026, up 5% on the second quarter. The product is used in lower-risk myelodysplastic syndromes (MDS). The company posted net income of $1.4 million for the period, announcing the results on 4 November 2026.

The company has started a gated European launch. Geron expects Rytelo to be available in Germany by the end of this year, with France to follow in 2027. The summary provided does not give details of the gating criteria or of other European markets.

Geron also lowered its 2026 operating expense guidance to a range of $220 million to $230 million.

Separately, the company disclosed that it is discontinuing the Phase 3 IMpactMF trial in myelofibrosis. According to the summary, a data monitoring committee concluded the study was unlikely to meet its overall survival endpoint. No new safety signals were identified. Further details on the committee's analysis were not available.

What it means for your team

  • Market-access teams should note the staggered European rollout: Germany is expected by year-end 2026 and France in 2027, with access described as gated.
  • Regulatory teams should note that the IMpactMF trial is being discontinued, so a myelofibrosis indication for imetelstat is not currently in prospect from this study.
  • Pharmacovigilance teams can note that the trial stoppage was not linked to any new safety signals, per the company's disclosure.

Company's press release (SEC filing): Geron Corp ↗

Article written by VigiEye from the official source (Geron Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →